The pyruvate dehydrogenase kinase inhibitor dichloroacetate mitigates alcohol-induced hepatic inflammation and metabolic disturbances in mice
Ethanol-induced hepatic inflammatory responses and metabolic disturbances were prevented by DCA in mice, indicating the potential to develop pyruvate dehydrogenase kinase inhibitors as an effective therapy to treat alcohol-associated liver disease.
Authors
- Megan R. McMullen (ORCID: https://orcid.org/0009-0007-6020-7125)
- Srinivasan Dasarathy (ORCID: https://orcid.org/0000-0003-1774-0104)
- Laura E. Nagy (ORCID: https://orcid.org/0000-0002-0580-2809)
- David Streem (ORCID: https://orcid.org/0000-0001-5804-7598)
- J. Mark Brown (ORCID: https://orcid.org/0000-0003-2708-7487)
- Jaividhya Dasarathy
- Nicole Welch (ORCID: https://orcid.org/0000-0002-4655-5146)
- Marko Mrdjen (ORCID: https://orcid.org/0000-0003-3000-0266)
- Jianguo Wu (ORCID: https://orcid.org/0000-0001-9801-5267)
- Annette Bellar
- Li Wang (ORCID: https://orcid.org/0000-0002-5542-6696)
- Vaibhav Singh (ORCID: https://orcid.org/0000-0001-5075-8045)
- Emily Huang (ORCID: https://orcid.org/0000-0002-7393-1282)
Institutions
- Cleveland Clinic (US)
- Cleveland Clinic Lerner College of Medicine (US)
- Community Health Systems - Lutheran Hospital (US)
- MetroHealth Medical Center (US)
- Case Western Reserve University (US)
Publication Details
- Journal
- Hepatology Communications
- Published
- 2024-11-29
- DOI
- https://doi.org/10.1097/hc9.0000000000000547
- Primary Topic
- Alcohol Consumption and Health Effects
- Type
- article
- Field-Weighted Citation Impact
- 0.00